Merrill maintains OSI at buy

OSI Pharmaceuticals, Inc. was maintained at a buy by Merrill Lynch analyst Eric Ende on news that the company reported better-than-expected profits of $35.7 million from Tarceva, compared to the analyst's estimate of $33.5 million. Merrill changed its loss-per-share estimates to $0.02 from $0.01in 2006 and to $0.91 from $1.14 in 2007. Shares of the Melville, N.Y., biopharmaceutical company were down 47 cents, or 1.72%, at $26.90 on volume of 1,346,582 shares versus the three-month running average of 1,434,860 shares. (Nasdaq: OSIP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.